BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260909T190000
DTEND;TZID=Africa/Nairobi:20260909T203000
DTSTAMP:20260924T170645Z
CREATED:20260909T140536Z
LAST-MODIFIED:20260924T170645Z
UID:41917-1788980400-1788985800@kesho-kenya.org
SUMMARY:Advancing Hodgkin Lymphoma Care
DESCRIPTION:ADVANCING HODGKIN LYMPHOMA CARE: INCORPORATING NOVEL THERAPIES INTO CLINICAL CARE \n\nModerator: Dr Peter Oyiro\nSpeakers: Dr Anne Mwirigi\, Prof Ranjana Advani\nDate: 10 September 2026\n\nThis session examined how Hodgkin lymphoma care is evolving as PET-adapted strategies and novel therapies become increasingly integrated into clinical practice\, while keeping cure\, toxicity and access in balance. \nDr Anne Mwirigi used clinical cases to highlight two practical challenges: treatment failure can still occur despite a negative interim PET\, and tissue confirmation remains essential when the clinical course changes. The discussion reinforced the need to pursue an adequate biopsy rather than rely on presumptive diagnoses\, particularly where lymphoma may be mistaken for conditions such as tuberculosis. \nProf Ranjana Advani reviewed contemporary treatment across early and advanced-stage disease. She discussed how more precise radiotherapy has reduced exposure to normal tissues\, while PET-adapted approaches continue to refine the balance between cure and long-term toxicity. In early-stage disease\, established combined-modality treatment remains important\, as current evidence does not yet support routinely replacing radiotherapy with novel agents. \nThe session also explored the expanding role of brentuximab vedotin and checkpoint inhibitors such as nivolumab and pembrolizumab in advanced\, relapsed and refractory Hodgkin lymphoma. In advanced disease\, novel-agent combinations are improving outcomes\, while treatment selection should consider disease risk\, physiological fitness and expected toxicity rather than age alone. \nAccess and affordability remained central to the discussion. The speakers highlighted the need for locally relevant research\, including collaborative studies of lower-dose checkpoint inhibition\, alongside stronger tumour boards\, shared pathology expertise\, registries and tissue banking. Across the session\, the message was clear: Hodgkin lymphoma care is moving toward greater individualization\, but better outcomes will also depend on stronger diagnostic and research systems. \nKey Takeaways \n\nA negative interim PET does not completely exclude later treatment failure.\nTissue diagnosis remains essential when lymphoma is suspected or disease behaviour changes.\nNovel agents are expanding options in advanced\, relapsed and refractory Hodgkin lymphoma.\nTreatment intensity should reflect disease risk\, physiological fitness and toxicity\, not age alone.\nAccess challenges strengthen the case for locally relevant research and stronger collaborative lymphoma systems.
URL:https://kesho-kenya.org/event/advancing-hodgkin-lymphoma-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-09-at-10.27.17-AM-e1788962859212.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260917T190000
DTEND;TZID=Africa/Nairobi:20260917T203000
DTSTAMP:20260924T171038Z
CREATED:20260917T130602Z
LAST-MODIFIED:20260924T171038Z
UID:41925-1789671600-1789677000@kesho-kenya.org
SUMMARY:Prostate cancer
DESCRIPTION:ADVANCES IN PROSTATE CANCER MANAGEMENT \n\nModerator: Prof Ngugi Mungai\nSpeakers: Prof Feng Wu\, Dr Palanki Satya Dattatreya\nDate: 17 September 2026\n\nThis session explored contemporary approaches to prostate cancer management\, bringing together advances in systemic therapy with emerging applications of high-intensity focused ultrasound (HIFU). \nDr Palanki Satya Dattatreya focused on the changing systemic treatment landscape across the prostate cancer continuum\, particularly metastatic castration-sensitive disease and non-metastatic castration-resistant prostate cancer. He emphasized the importance of moving beyond androgen deprivation therapy (ADT) alone for most patients and considering earlier treatment intensification with androgen receptor pathway-targeted therapies. \nA key theme was the need to define disease burden and presentation at the outset. Distinguishing between low- and high-volume disease\, and between de novo and recurrent metastatic disease\, can help guide treatment selection and provide important prognostic information. The session also reviewed the evidence supporting doublet and\, in selected fit patients\, triplet therapy\, while highlighting the importance of tailoring treatment to disease volume\, patient fitness and expected toxicity. \nThe presentation reviewed the role of next-generation androgen receptor pathway inhibition and highlighted PSA doubling time as an important marker in non-metastatic castration-resistant prostate cancer\, helping identify patients at higher risk of developing metastatic disease. \nDuring the discussion\, Dr Dattatreya reinforced that treatment decisions should not rely on chronological age alone. Physiological fitness\, performance status\, comorbidity\, expected toxicity and patient preference remain important when deciding how aggressively to intensify treatment. \nProf Feng Wu introduced HIFU as a non-invasive ablative technology that concentrates ultrasound energy within a defined target\, producing rapid local thermal injury and coagulative necrosis while avoiding surgical incisions. He reviewed its established and evolving applications in benign prostatic hyperplasia and presented early clinical experience in localized prostate cancer. \nHis presentation highlighted the precision required for HIFU\, including ultrasound or MRI guidance for treatment planning and monitoring. The discussion also addressed one of the challenges of focal treatment in prostate cancer: accurate tumour localisation. Some prostate cancers may not be clearly visible on MRI\, making biopsy information important when defining treatment targets and deciding between focal and whole-gland approaches. \nAcross the session\, a consistent message emerged: prostate cancer management is becoming increasingly individualized. Disease volume\, stage\, biology\, patient fitness\, treatment tolerance and access to newer technologies all influence the choice and sequencing of therapy. The expanding range of systemic and local treatment options makes multidisciplinary assessment increasingly important in determining the most appropriate pathway for each patient. \nKey Takeaways \n\nADT alone now has a limited role in many patients with advanced hormone-sensitive prostate cancer\, with treatment intensification increasingly central to contemporary management.\nDisease volume\, risk and whether metastatic disease is de novo or recurrent should be assessed early because these factors influence prognosis and treatment selection.\nNext-generation androgen receptor pathway therapies have expanded systemic treatment options across metastatic hormone-sensitive and non-metastatic castration-resistant disease.\nTreatment intensity should be individualized according to physiological fitness\, disease characteristics and expected toxicity rather than chronological age alone.\nHIFU is a non-invasive local treatment option for selected localized prostate cancers\, but accurate tumour localisation is critical.\nMultidisciplinary decision-making remains essential as treatment becomes more individualized.
URL:https://kesho-kenya.org/event/prostate-cancer-9/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-17-at-3.58.00-PM-e1789650329636.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260924T190000
DTEND;TZID=Africa/Nairobi:20260924T203000
DTSTAMP:20260924T170220Z
CREATED:20260924T165755Z
LAST-MODIFIED:20260924T170220Z
UID:41931-1790276400-1790281800@kesho-kenya.org
SUMMARY:Cure in Chronic Myeloid Leukemia
DESCRIPTION:Beyond Control: Advancing Towards a Cure in Chronic Myeloid Leukemia \nDate & Time: 24th September 2026\, 7 PM – 8:30 PM EAT \nSpeakers: \n\nProf. Malkit Riyat — Associate Professor of Haematology and Consultant Haematologist\, Aga Khan University Hospital\nTopic: “The CML Care Pathway in Kenya: Optimising Treatment\, Molecular Monitoring and Access to Treatment-Free Remission”\nProf. Mhairi Copeland — Professor of Translational Haematology & Consultant Haematologist; Chair\, UK Blood Cancer Research Network; President\, Scottish Haematology Society\, University of Glasgow\nTopic: “Can CML Be Cured? Emerging Science and Global Progress Beyond Treatment-Free Remission”\nDr. Matilda Ong’ondi — Consultant Physician and Clinical Haemato-Oncologist at the Kenyatta National Hospital\n\n    	\n        Click to Register
URL:https://kesho-kenya.org/event/cure-in-chronic-myeloid-leukemia/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-24-at-12.02.45-PM-e1790269179155.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260602T074510Z
CREATED:20260407T183641Z
LAST-MODIFIED:20260602T074510Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-06-02-at-10.31.48-AM-e1780386294605.jpeg
END:VEVENT
END:VCALENDAR